Download Free Medical Overview of Interstitial Cystitis for the Primary Care Physician PowerPoint Presentation

Overview of Interstitial Cystitis for the Primary Care Physician PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Obstetrics & Gynecology, which is titled "Overview of Interstitial Cystitis for the Primary Care Physician", to know about incidence, epidemiology and pathogenesis of Interstitial Cystitis (IC), key concepts in the physical examination of the IC patient, and the concept of multimodal therapy for the treatment of IC.

Tags : Obstetrics, Gynecology, Overview, Interstitial Cystitis, incidence, epidemiology, pathogenesis

Published on : Jul 18, 2021 | Views : 1772 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Overview of Interstitial Cystitis for the Primary Care Physician WVU WOMENS HEALTH CURRICULUM Stanley Zaslau, MD, MBA, FACS Program Director & Associate Professor Section of Urology West Virginia University
Slide 2-

Objectives In this lecture, participants will learn: Incidence, epidemiology and pathogenesis of Interstitial Cystitis (IC) Understand the role of the urothelium in the prevention and treatment of IC. Key concepts in the physical examination of the IC patient Understand the concept of multimodal therapy for the treatment of IC.
Slide 3-

Objectives In this lecture, participants will learn: Key treatments of IC Antidepressants Gabapentin Intravesical therapy Pentosan polysulfate Neuromodulation Sexual dysfunction in the IC patient – pathogenesis and treatment strategies
Slide 4-

Introduction Challenge to diagnose “Traditional” view recognizes patients with end-stage disease A continuum--rather than a “fixed” disease Confused with other GU or GYN disorders
Slide 5-

Definition First reported in 1915 NIH criteria established in 1987 characterize IC syndrome patient describe advanced disease do not define IC criteria represent a small part of the IC population
Slide 6-

Definition C. Lowell Parsons, MD The triad of urinary urgency, frequency, and bladder or pelvic pain in the absence of bacterial infection or other definable pathology is the definition of interstitial cystitis Grannum Sant, MD Interstitial Cystitis (IC) Interstitial cystitis is urgency, frequency, and pain in the absence of a defined etiology
Slide 7-

“Better” Definitions Clinical syndrome Gradually progressive Time line concept: 20’s: mild, intermittent urgency with UTI 30’s: urethral syndrome (persistent -Cx) 40’s: meets NIH criteria for IC 60’s: severe, constant symptoms c/w IC
Slide 8-

Pelvic Pain Urgency Frequency ± Incontinence Clinical Picture of IC Urgency, frequency, nocturia, chronic pelvic pain (CPP) Pain associated with sexual intimacy +/- incontinence Negative culture and sensitivity 1. Parsons CL.
Slide 9-

Epidemiology Affects 2.5 million women in US Significant number of men affected Studies: Finnish: incidence 1.2 cases/100,000 people prevalence of 10-11/100,000 Held: 44,000 cases in US; prevalence of 450,000 cases May only reflect end-stage disease
Slide 10-

Epidemiology More recent studies 284 UCSD Female MS attending lectures All filled out PUF questionnaire 8 items symptom, bother and total score pelvic pain urgency frequency 24% had scores > 10 Parsons, et al Urol 2002
Slide 11-

Increasingly a Concern in Women Estimated prevalence of self-reported IC in women is 1.5 million1 IC is often misdiagnosed or underdiagnosed 38% of women scheduled for laparoscopy for suspected endometriosis were cystoscopically confirmed to have IC2 IC may be a common cause of Chronic Pelvic Pain (CPP) 80% to 85% of women with CPP of unidentified etiology shown to have pain of bladder origin3 1. Curhan GC et al. J Urol. 1999;161:549-552. 2. Clemons JL et al. 2002;100:337-341. 3. Parsons CL et al. Obstet Gynecol. 2001;98:127-132.
Slide 12-

Consider IC Possible Presentations Failed Endometriosis Therapy Nonbacterial Prostatitis Recurrent UTI Symptoms Overactive Bladder Treatment Failures Urgency Frequency Pain – Dyspareunia Refractory Patients New Patients 1. Parsons CL et al. Female Patient. May 2002(suppl):12-17. 2. Chung MK et al. JSLS. 2002;6:311-314. 3. Miller JL et al. Urology. 1995;45:587-590.
Slide 13-

Diagnostic considerations for the Primary Care Physician For patients with: urgency frequency dysuria painful with sexual intercourse negative urine cultures and urine cytologies SUSPECT INTERSITIAL CYSTITIS
Slide 14-

Physical Examination Females anterior vaginal wall tenderness suprapubic tenderness pelvic floor dysfunction Males suprapubic tenderness sphincter spasm tender rectal examination
Slide 15-

IC Evaluation Tools for the Primary Care Physician Routine testing for the PCP urine analysis urine culture urine cytology voiding diary Additional testing to be undertaken by the urologist cystourethroscopy and urodynamics KCL testing
Slide 16-

Voids per day Statistics (mean) Normal population: 6.5times/day IC population: 16.5 times/day
Slide 17-

Anesthetic Bladder Capacity Normal people: 1100 cc IC patients: 575 cc
Slide 18-

Clinical Approach to IC: A Primer for the Primary Care Physician Female History ICSI PUF Physical exam Urinalysis and/or culture Elective tests Potassium sensitivity test Cystoscopy and hydrodistention Cystometrogram Urine for cytology Male History ICSI CPSI PUF Physical exam Urinalysis and/or culture Elective tests PPMT Potassium sensitivity test Cystoscopy and hydrodistention Cystometrogram Urine for cytology ICSI = Interstitial Cystitis Symptom Index. PUF = Pelvic Pain and Post-Prostate Massage Test. 1.
Slide 19-

Pathogenesis Vascular insufficiency Epithelial leak Role of Urinary Potassium Neural Up-regulation Mast Cells
Slide 20-

Epithelial Leak Leak --> impaired migration of solutes across epithelium “Leak assay” studies (75% + in IC) Potassium sensitivity test + in 90% suggest leaky epithelium may suggest neurological inflammatory component
Slide 21-

Role of Urinary Potassium Principle toxic substance in urine is potassium Toxic to human cells Urine concentration 75 mEq/L Levels > 15 mEq/L depolarize sensory nerves and muscle
Slide 22-

Role of Urinary Potassium Effects of excessive K+ back diffusion: vascular destruction lymphatic destruction sensory nerve & muscle depolarization up-regulation of mast cells induction of substance P and up-regulation of pain fibers disease progression
Slide 23-

Potassium Sensitivity May Be a Good Predictor of IC Detects abnormal bladder epithelial permeability Positive in 70% to 90% of IC patients 81% of gynecologic patients with pelvic pain had increased potassium sensitivity 1. Parsons CL et al. J :1054-1057.
Slide 24-

Role of Urinary Potassium Sodium chloride instillation does not cause symptoms Conclusion: individual potassium sensitivity: useful diagnostic tool for IC useful even in patients with mild symptoms useful when one is unsure of the diagnosis
Slide 25-

Neural Up-regulation Up-regulation of sensory nerves in the bladder Seen in severe forms of IC Difficult to treat Can persist after treatment of epithelial defect
Slide 26-

Mast Cells Role not fully understood Present in IC and non-IC bladders Causative or secondary role in IC? Cause: degranulate & produce symptoms Secondary: response to epithelial leak Interact with sensory nerves & release neurotransmitters that activate pain
Slide 27-

Glycosaminoglycan (GAG) Layer in IC GAG, a mucoprotein, is a component of bladder epithelium GAG may be essential for bladder protection Irritants and toxins in urine Bacterial adherence GAG deficiency may result in pathologic changes associated with IC Permeability of urothelium Inflammatory/allergic response Lilly JD, Parsons CL.;171:493-496.
Slide 28-

Vicious Cycle of IC Bladder Insult Epithelial Layer Dysfunction More Injury
Slide 29-

Principles of Treatment--Multimodal Dietary guidelines Stabilize the urothelium pentosan polysulfate Modulate neural activity Tricyclic antidepressants like amitriptyline, gabapentin Stabilize mast cells Antihistamines, ex. Hydroxyzine Stabilize the pelvic floor sacral neuromodulation
Slide 30-

Pentosan Polysulfate Mechanism: re-establish GAG layer function and decrease K+ leak The only FDA-approved oral therapy proven effective for IC pain or discomfort Reduces painful symptoms long-term Dose: 100 mg TID (200 mg BID) Full effect takes up to 6 months Side effects: headache, GI upset, hair loss
Slide 31-

Antihistamines Role: blockade of mast cell release of histamine Dose: 25 mg to 75 mg qHS Useful: allergy sufferers (spring/fall) Adverse: sedative properties
Slide 32-

Antidepressants Role: decrease neural pain, decrease urgency and frequency (Ach effect) Dose: 25 mg to 100 mg qHS amitriptyline Some patients respond to lower doses (10 mg) SSRI can also be considered (watch for drug-induced FSD
Slide 33-

Gabapentin Role: inhibit neural up-regulation and neurogenic spinal cord inflammation Use: chronic unrelenting pain Dose: 300 mg to 2400 mg/day Side effects: sedation Advise: careful dose titration to balance sedative properties
Slide 34-

Intravesical Agents Dimethyl Sulfoxide (DMSO) Principle FDA approved intravesical agent Instilled once weekly for at least 6 weeks Cocktails: DMSO, sodium bicarbonate, heparin, triamcinolone, bupivicaine 50% objective response rate
Slide 35-

Sacral Neuromodulation Rationale Disrupt afferent inputs to the bladder and pelvic floor that cause pathologic voiding Specifically help regulate capsaicin-sensitive C-afferent neurons originate from sacral parasympathetic plexus may relieve pelvic pain/muscle spasm neural input through the pelvic nerve may aid in detrusor contraction
Slide 36-

Sacral Neuromodulation Goals of sacral neuromodulation Therapy Improve pelvic pain Improve urinary frequency Improve voided volumes Improve overall symptom scores IC Symptom Index Chronic Prostatitis Symptom Index
Slide 37-

Sacral Neuromodulation Potential uses of sacral neuromodulation Refractory urinary urge incontinence Non-obstructive urinary retention Refractory urinary urgency and frequency Interstitial Cystitis
Slide 38-

Sacral Neuromodulation Current Literature Refractory Urgency/Frequency (IC) Comiter C. 25 patients, prospective study Mean age 47 years Trial of sacral nerve stimulation 50% improvement in frequency 50% improvement in nocturia 50% improvement in voided volume 50% improvement in pain 17/25 qualified for permanent implant
Slide 39-

Sacral Neuromodulation Current Literature Prospective study for refractory IC Mean follow up: 14 months Parameters: Daytime frequency: 17 ---> 8.7 voids (p<0.01) Nocturia: 4.5 ---> 1.1 voids (p<0.01) Mean Voided Volume: 111 cc ---> 264 cc (p<0.01) Pain (1-10 scale): 5.8/10 to 1.6/10 (p<0.01) IC Symptom Index: 16.5 ---> 6.8 (p<0.01)
Slide 40-

Sacral Neuromodulation Current Literature Prospective study for refractory IC 16/17 (94%) had improvement in all parameters at last follow up Conclusions Sacral neuromodulation is safe and effective treatment of dysfunctional voiding/pelvic pain Useful treatment for refractory IC symptoms Comiter CV. J Urol 2003 Apr;169(4):1369-73.
Slide 41-

Sacral Neuromodulation Current Literature West Virginia University Hospital Experience Collaborative model (Pain Treatment Center and Urology) All patients evaluated with cystoscopy and urodynamics prior to test stimulation 2 stage approach (test stimulation -> permanent implant
Slide 42-

Sacral Neuromodulation Current Literature West Virginia University Hospital Experience To date: 210 test stimulations 195 permanent implants 80 implants have refractory urgency/frequency (IC) Mean age 51 years Mean follow up is 2 year (longest out is 3 years) All with improvement in symptoms and voided volume as well as decline in pelvic pain/bladder spasm Zaslau S, et al. West Virginia Medical Journal, August, 2003
Slide 43-

Sexual Problems Affecting the IC Patient Pain associated with intercourse Entry dyspareunia Deep dyspareunia
Slide 44-

Entry Dyspareunia “Pain at the opening” Atrophic vaginitis post menopausal women estrogen loss Tx: topical or oral estrogen replacement Vaginitis infectious (fungal) Tx: oral or topical antifungal agents
Slide 45-

Entry Dyspareunia Herpes vulvitis must rule out other causes first! Vulvodynia vulvar pain of unknown cause “feels like dragging sandpaper thru open wound” Infectious vulvitis glandular enlargement; tx: antibiotics
Slide 46-

Deep Dyspareunia Most common type of dyspareunia in IC Sources of pain: Vaginal infections Vaginal dryness estrogen loss psychological stress
Slide 47-

Deep Dyspareunia Bladder pain pain in front portion of vagina caused by penile pressure on bladder trigone Pain from other pelvic abnormalities endometriosis ovarian diseases pelvic infections diverticulosis
Slide 48-

Deep Dyspareunia Pain from pelvic floor muscles most common source of pain for IC patient pelvic floor spasm occurs in 70% of IC patients can prevent penile insertion
Slide 49-

Vicious cycle of muscle spasm 1. SPASM OF PELVIC MUSCLES 2. FEAR OF PAIN WITH PENETRATION PENILE PENETRATION 3. MORE MUSCLE TIGHTENING 4. PENIS PENETRATES INTO SPASTIC, TENDER MUSCLES 5. FURTHER TIGHTENING OF MUSCLES
Slide 50-

IC and Female Sexual Dysfunction (FSD) 100 patients with IC FSFI administered Assess 6 domains of sexual function Desire Arousal Orgasm Lubrication Satisfaction Pain
Slide 51-

IC and FSD Results: Mean age 39 years Impairment in all domains “50-75% of the time” Conclusions FSD in IC involves more than pelvic pain Zaslau, S et al FSFF, Vancouver, BC 2002
Slide 52-

FSD in IC: 1st 400 Patients 400 IC patients FSFI administered on line at IC-Network Compared to two groups Controls (131) Female sexual arousal disorder (129)
Slide 53-

FSD in IC 1st 400 Patients Results Statistically significant decrease in all domains when compared to controls Stastically significant decrease in all domains when compared to Arousal Disorder Group Lowest scores: pain Zaslau, et al AUA 2003, Chicago, IL.
Slide 54-

Conclusions: IC and FSD Global sexual dysfunction affecting all domains May be age related and progressive Pain domain has lowest scores Treatment is multimodal and may involve counseling, sex therapy and physical therapy
Slide 55-

General Treatment Principles Talk to your partner create “game plan” to deal with partner needs role for physician, social worker, sex therapist Don’t focus only on penetration Shift major focus to foreplay, full body massage, deep kissing, fondling, oral-genital contact
Slide 56-

General Treatment Principles Watch out for medication effects on orgasm medications can cause fatigue and/or loss of sexual desire antidepressants impair orgasm Go slow forget the terrible memories Relax to prevent pelvic muscle spasm Go slow with insertion and thrusting
Slide 57-

General Treatment Principles Lots of lubrication aids in penetration especially helpful in vulvodynia Be in control goes along with going slow let the patient call the shots communicate!
Slide 58-

General Treatment Principles Find the right position There is no “perfect position” Goal: minimize vaginal tenderness, adjust vault-penis angle and partner weight Missionary: most discomfort for female partner (penile-->bladder base pressure) Female superior: more control for IC female
Slide 59-

General Treatment Principles Go one step at a time Step-wise approach for vaginal penetration First goal: NOT penis in vagina = orgasm! Don’t focus on vaginal entry initially Instead: superficial penetration and maximize foreplay
Slide 60-

General Treatment Principles Avoid intercourse during flares Flare can be related to menses Increased urinary frequency and pelvic pain = flare Focus away from intercourse and onto foreplay! Take advantage of remissions take things slow; “roll with the punches”
Slide 61-

General Treatment Principles Take a warm bath after sex can relax pelvic floor muscles can be therapeutic after sex however, warmth can be irritating! Avoid urinary tract infections void before and after sexual relations Avoid use of diaphragm can increase UTI and pelvic pain/irritation
Slide 62-

General Treatment Principles Use vaginal dilators/biofeedback can relax vaginal vault patient in total control of insertion step-wise treatment strategy minimizes anxiety
Slide 63-

General Treatment Principles Read and learn more about IC Interstitial Cystitis Association (www.ichelp.org) Interstitial Cystitis Network (www.ic-network.com)
Slide 64-

Summary Interrelationships between conditions: Overactive Bladder No bacteriuria No bladder pain Urinary Tract Infection Bacteriuria and bladder pain Interstitial Cystitis Bladder pain and no bacteriuria
Slide 65-

Summary (continued) The prevalence of IC is much higher than previously estimated IC should be considered in patients who have failed standard therapy for endometriosis (prior to hysterectomy), OAB, or have symptoms of recurrent/chronic UTI and do not improve on antibiotics Increase awareness of IC as part of CPPS differential diagnosis Symptoms of CP/CPPS appear to be similar to IC Treatment of IC is multimodal (pentosan polysulfate, antidepressants, antihistamines, role for sacral neuromodulation in treatment failures) *NBP = non-bacterial
Slide 66-

References – 1 Peters KM, Killinger KA, Carrico DJ, Ibrahim IA, Diokno AC, and Graziottin A: Sexual Function and Sexual Distress in Women with Interstitial Cystitis: A Case Control Study. Urology. 2007; 70(3): 543-547. Zaslau S, Triggs J, Morgan L, Osborne J, Subit M, Riggs D: “Characterization of Female Sexual Dysfunction in Patients with Interstitial Cystitis.” Presented at the American Urological Society Meeting, Chicago, IL, April 27, 2003.
Slide 67-

References - 2 Zaslau S, Subit MJ, Mohseni HF, Riggs D, Jackson B, Kandzari S: “Sexual Dysfunction in Patients with Interstitial Cystitis.” Presented at the American Urogynecology Meeting, Hollywood, FL, September 12, 2003. Zaslau S, Subit MJ, Mohseni HF, Riggs D, Jackson B, Kandzari S. “Sexual Dysfunction in Patients with Interstitial Cystitis: Initial Analysis of Under 40 Cohort.” Presented at the Mid-Atlantic Section of the American Urological Society Meeting, Boca Raton, FL, October 26-29, 2003.
Slide 68-

References - 3 Zaslau S: Blueprints in Urology, 1st ed. Boston, MA: Blackwell Science, Inc., 2004. Zaslau S: SOAP Notes in Urology, 1st ed. Baltimore, MD: Lippincott Williams and Wilkins, Inc., 2006. Messing EM. Interstitial cystitis and related syndromes. In: Campbell’s Urology, 6th Edition. Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds). Philadelphia: WB Saunders Co., Volume 1, Chapter 24, pp. 982-1005, 1992.